The Safety and Benefit of Statins in Liver Cirrhosis: a Review

Abstract

Dyslipidemia is a primary, major risk factor for coronary artery disease CAD. The prevalence of dyslipidemia had decreased over the past 30 years, which may in part be explained by the steady increase in the use of lipid-lowering drug therapy, especially statins. Cardiovascular risk has been shown to be greater in liver disease (20% in the liver cirrhosis vs. 12% in the general population), where statins can play an important role as a primary and secondary prevention for CAD. Given patients with chronic liver disease, especially liver cirrhosis are at risk of decreased hepatic clearance, there is concern that this patient population may be at higher risk for complications from statin therapy. Several retrospective studies showed that statin use in chronic liver disease and cirrhosis is safe, and even it was associated with lower mortality and lower rate of hepatic decompensation. This review discusses the safety and the different mechanisms where statins can decrease the rate of complications in liver cirrhosis, including portal hypertension, sepsis and the incidence of hepatocellular carcinoma.

Key words

liver cirrhosis - statins - decompensation - safety - hepatocellular carcinoma

• References

• 1 Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209
• 2 Nicholls S, Lundman P. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med 2004; 4: 187-195
• 3 Cohen JD, Cziraky MJ, Cai Q et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006. Am J Cardiol 2010; 106: 969-975
• 4 cdc [e-mail]. Centers for disease control and prevention. National Center for Health Statistics [Accessed 2012]
• 5 Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. The European Association for the Study of the Liver 2013; 978-2-8399-1176-4
• 6 Targher G, Bertolini L, Padovani R et al. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46: 1126-1132
• 7 Kalaitzakis E, Rosengren A, Skommevik T et al. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci 2010; 55: 467-475
• 8 Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 415-433
• 9 Calderon RM, Cubeddu LX, Goldberg RB et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010; 85: 349-356
• 10 Argo CK, Loria P, Caldwell SH et al. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 2008; 48: 662-669
• 11 Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007; 99: 732-738
• 12 Chang CY, Schiano TD. Drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135-1151
• 13 Bhardwaj SS, Chalasani N. Lipid lowering agents that cause drug induced hepatotoxicity. Clin Liver Dis 2007; 11: 597-613
• 14 Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374-1380
• 15 Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004; 71: 58-62
• 16 Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695
• 17 Khorashadi S, Hasson NK, Cheung RC et al. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006; 4: 902-907
• 18 William N, Mahmud M. Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep 2013; 15: 305
• 19 Avins AL, Manos MM, Zhao W et al. Hepatic effects of lovastatin exposure in patients with liver disease. Drug Saf 2008; 31: 325-334
• 20 Sonal K, Norman D, Grace Amir A et al. Statin use in patients with cirrhosis: A retrospective cohort study. Dig Dis Sci 2014;
• 21 Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-329
• 22 Gupta TK, Toruner M, Chung MK et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-931
• 23 Dangas G, Smith DA, Unger AH et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-692
• 24 Kalinowski L, Dobrucki LW, Brovkovych V et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933-938
• 25 Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010
• 26 Carmen Z, Juan G Abraldes et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-755
• 27 Juan G, Abralde Albillos A. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658
• 28 Kim WR, Brown Jr RS, Terrault NA et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242
• 29 Cazzaniga M, Dionigi E, Gobbo G et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in hospital outcome. J Hepatol 2009; 51: 475-482
• 30 Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-1164
• 31 Motzkus-Feagans C, Pakyz AL, Ratliff SM et al. Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther 2013; 38: 611-618
• 32 Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
• 33 Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50
• 34 Demierre MF, Higgins PD, Gruber SB et al. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942
• 35 Rao S, Porter DC, Chen X et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96: 7797-7802
• 36 Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37
• 37 Siddharth S, Preet Paul S, Abha Goyal S et al. Associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332
• 38 David E, Cohen Frank A. et al. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 [suppl] 77C-81C